GlaxoSmithKline has long explored a sale of some $3 billion worth of its older drugs, planning to shed products by geographic region to meet buyers' interests. Now, the company could have a more enticing offer on its hands as private equity firm Apollo Global Management is planning to bid GSK's entire portfolio of drugs, rather than snatch up businesses by region, people familiar with the process told Reuters.
With Pfizer's eligibility to bid again for AstraZeneca nearing, the drug giant seems unlikely to make another run at its one-time target, industry-watchers say. But that doesn't mean it isn't prepping a run at someone else.
For three years, Guido Rasi has been Europe's top pharma regulator, moving aggressively to restore the image of the European Medicines Agency. But his future there is now in doubt, sidelined by a colleague who was miffed that he was not picked for the job himself, the Financial Times reports.
With drugs like Yervoy and Sprycel leading its comeback and a pipeline filling up with more biologics, Bristol-Myers Squibb needs someplace to make them, and Ireland will get the prize--an investment of nearly $1 billion and the 400 jobs that will come with it.
AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.
Pfizer inked a deal with the Bill & Melinda Gates Foundation to roll out a long-acting contraceptive in 69 of the world's poorest countries.
Bolstering sales of Brilinta has been a central focus for AstraZeneca CEO Pascal Soriot as of late, and now the British drugmaker is embarking on another project designed to add some shine to the drug.
The FDA's new due diligence on generic drugs now has one victim: Mallinckrodt, which makes a knockoff version of Johnson & Johnson's ADHD drug Concerta. The Dublin-based drugmaker says the FDA is questioning whether its generic actually measures up to the brand.
More than two dozen top-selling cancer drugs are on a hit list in the U.K. The country's Cancer Drugs Fund, designed to cover oncology meds not approved by cost-effectiveness watchdogs, plans to take a sharp look at these drugs at a meeting next month. And some of them may find themselves shut out for funding--unless new discount plans are in the offing.
Merck KGaA has long struggled to ramp up its sagging drug portfolio. Now, the German drugmaker is enjoying a change in the wind, announcing third-quarter earnings buoyed by sales of its multiple sclerosis med Rebif and progress in emerging markets.
Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan--and word is it could happen quickly.
Takeda Pharmaceuticals saw a problem with recent obesity drug launches: Cost. Private insurers and public payers were refusing coverage--or foisting big copays onto patients--dragging down new drugs marketed by Vivus and Eisai.
Branded trinkets evoke memories of pharma marketing days past, when reps carried bags full of gifts to promote their products. Now, tougher policies have most tchotchkes collecting dust.
Rumor has it, thanks to potential white knight Actavis, Bill Ackman and Valeant face a serious threat to their Allergan hostile bid. But Ackman may already be preparing for another move.
Italy: the land of good food, rich history and pharma billionaires. The country boasts a number of pharma giants in its ranks thanks to recent deals and the continued success of decades-old businesses.
No question, the hepatitis C drug market is about to get even more interesting. With AbbVie's three-drug regimen up for approval before the end of the year, and Merck and Bristol-Myers Squibb racing up behind, the market share tussle with current players Gilead Sciences and Johnson & Johnson is coming.
India's Cadila Pharmaceuticals has run afoul of the FDA for not doing enough to track down the source of impurities in some products and failing to investigate when customers complained about odors emanating from its APIs.
A decade-long class action lawsuit against Pfizer over alleged off-label Neurontin marketing is finally wrapping up, with U.S. District Judge Patti Saris approving a $325 million settlement on Monday.
Roche's Genentech unit is facing more pushback over distribution-channel changes for its three best-selling cancer treatments. Leaders from top U.S. teaching hospitals and medical institutions are asking Congress for an "expedited review" of the Roche unit's decision.
It's an established fact: Many patients don't take their meds as directed. Another established fact: That failure costs the healthcare system hundreds of billions. A third: Solutions are difficult to come by.